{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:47:18Z","timestamp":1789372038331,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jtos.2014.05.005","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T04:01:05Z","timestamp":1406001665000},"page":"273-284","source":"Crossref","is-referenced-by-count":98,"title":["Treatment of Blepharitis: Recent Clinical Trials"],"prefix":"10.1016","volume":"12","author":[{"given":"Stephen C.","family":"Pflugfelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2014.05.005_bib1","unstructured":"American Academy of Ophthalmology. Preferred Practice Pattern: Blepharitis. October 2011 revision. Available at: http:\/\/one.aao.org\/CE\/PracticeGuidelines\/PPP_Content.aspx?cid=500cd9ca-173c-4c31-b6ea-a258e3549474. Accessed June 6, 2013"},{"issue":"2 suppl","key":"10.1016\/j.jtos.2014.05.005_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1542-0124(12)70620-1","article-title":"Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment","volume":"7","author":"Lemp","year":"2009","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2014.05.005_bib3","first-page":"5","article-title":"Interventions for chronic blepharitis (Review)","volume":"16","author":"Lindsley","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtos.2014.05.005_bib4","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1167\/iovs.11-9228","article-title":"Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain","volume":"53","author":"Viso","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/08820538.2010.488562","article-title":"Blepharitis","volume":"25","author":"Bernardes","year":"2010","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00006324-199009000-00010","article-title":"Prevalence of Meibomian gland dysfunction","volume":"67","author":"Hom","year":"1990","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib7","first-page":"16","article-title":"Ocular demodicosis","volume":"109","author":"Patel","year":"2013","journal-title":"W\u00a0V Med J"},{"issue":"2 suppl","key":"10.1016\/j.jtos.2014.05.005_bib8","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1542-0124(12)70624-9","article-title":"The role of bacteria in blepharitis","volume":"7","author":"O\u2019Brien","year":"2009","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2014.05.005_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bjo.2010.201194","article-title":"The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp","volume":"95","author":"Filho","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/09286586.2011.642052","article-title":"Association of blepharitis with Demodex: a meta-analysis","volume":"19","author":"Zhao","year":"2012","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.jtos.2014.05.005_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.envres.2011.11.010","article-title":"Ambient levels of air pollution induce clinical worsening of blepharitis","volume":"112","author":"Malerbi","year":"2012","journal-title":"Environ Res"},{"key":"10.1016\/j.jtos.2014.05.005_bib12","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1167\/iovs.12-11361","article-title":"Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease","volume":"54","author":"Tes\u00f3n","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib13","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction","volume":"52","author":"Geerling","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.icl.0000247638.50568.c0","article-title":"Comparison of the efficacy of two lipid emulsion eye drops in increasing tear film lipid layer thickness","volume":"33","author":"Scaffidi","year":"2007","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2014.05.005_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2147\/OPTH.S35833","article-title":"Efficacy of an artificial tear emulsion in patients with dry eye associated with meibomian gland dysfunction","volume":"7","author":"Sindt","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ajo.2007.01.054","article-title":"Corneal manifestations of ocular demodex infestation","volume":"143","author":"Kheirkhah","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ajo.2010.11.024","article-title":"Clinical treatment of ocular Demodex folliculorum by systemic ivermectin","volume":"151","author":"Holzchuh","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ajo.2007.03.032","article-title":"Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus","volume":"144","author":"Freidlin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ajo.2011.03.010","article-title":"Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study","volume":"152","author":"Haas","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/jop.2012.0081","article-title":"Comparative in\u00a0vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible\/nonsusceptible staphylococci","volume":"29","author":"Miller","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ajo.2008.01.025","article-title":"Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates","volume":"145","author":"Asbell","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s40123-013-0020-5","article-title":"Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they the same?","author":"Pleyer","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","article-title":"Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction","volume":"25","author":"Perry","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A\u00a0randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/jop.2006.22.47","article-title":"Efficacy of topical cyclosporine 0.05% in the treatment of posterior blepharitis","volume":"22","author":"Rubin","year":"2006","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/ICO.0b013e3181d836f3","article-title":"Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction","volume":"29","author":"Maskin","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib27","first-page":"336","article-title":"The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis)","volume":"106","author":"Macsai","year":"2008","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jtos.2014.05.005_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00003226-200303000-00002","article-title":"Systemic linoleic acid therapy in dry eye syndrome with an inflammatory component","volume":"22","author":"Barabino","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib29","first-page":"448","article-title":"Efficacy assessment of Nutrilarm\u00ae a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome","volume":"34","author":"Creuzot-Garcher","year":"2011","journal-title":"J\u00a0Fr Ophthamol"},{"key":"10.1016\/j.jtos.2014.05.005_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.clae.2007.12.001","article-title":"Oral omega-6 essential fatty acid treatment in contact lens associated dry eye","volume":"31","author":"Kokke","year":"2008","journal-title":"Cont Lens Anterior Eye"},{"key":"10.1016\/j.jtos.2014.05.005_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/ICO.0b013e318299549c","article-title":"Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial","volume":"32","author":"Sheppard","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib32","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1111\/j.1755-3768.2011.02196.x","article-title":"A\u00a0multicenter, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients","volume":"89","author":"Brignole-Baudouin","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib33","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1167\/iovs.04-1394","article-title":"Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sj\u00f6gren\u2019s syndrome patients","volume":"46","author":"Aragona","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/ICO.0b013e318033d79b","article-title":"Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction","volume":"26","author":"Pinna","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3129\/i08-016","article-title":"Blepharitis: current strategies for diagnosis and management","volume":"43","author":"Jackson","year":"2008","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","article-title":"Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis","volume":"75","author":"Fadlallah","year":"2012","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1185\/03007995.2010.539603","article-title":"Evaluation of clinical efficacy and safety of tobramycin\/dexamethasone ophthalmic suspension 0.3%\/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis\/blepharoconjunctivitis","volume":"27","author":"Torkildsen","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2014.05.005_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","article-title":"Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis","volume":"94","author":"Opitz","year":"2011","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.jtos.2014.05.005_bib39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","article-title":"Topical azithromycin therapy of meibomian gland dysfunction: clinical response and lipid alterations","volume":"29","author":"Foulks","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","article-title":"Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis","volume":"29","author":"Haque","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib41","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","article-title":"Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis","volume":"25","author":"Luchs","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jop.2009.0026","article-title":"Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation","volume":"25","author":"Akpek","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib43","first-page":"804","article-title":"Postantibiotic effects of eleven antimicrobials on five bacteria","volume":"22","author":"Wang","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jtos.2014.05.005_bib44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00417-009-1039-0","article-title":"A\u00a0prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis","volume":"247","author":"Yactayo-Miranda","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib45","unstructured":"John G. A comparative study in the clinical and microbial efficacy of topical besifloxacin ophthalmic suspension 0.6% with erythromycin ophthalmic ointment 0.5% for the management of acute blepharitis (poster). Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 6-9, 2012"},{"key":"10.1016\/j.jtos.2014.05.005_bib46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656561003667532","article-title":"Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens","volume":"11","author":"Comstock","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jtos.2014.05.005_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bjo.2006.103556","article-title":"3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children","volume":"91","author":"Cochereau","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib48","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.06-1413","article-title":"AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis","volume":"48","author":"Protzko","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2014.05.005_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00061198-199510000-00010","article-title":"Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma","volume":"4","author":"Clark","year":"1995","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.jtos.2014.05.005_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1185\/03007995.2012.659723","article-title":"A\u00a0multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis","volume":"28","author":"Chen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2014.05.005_bib51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","article-title":"Comparison of the safety and efficacy of loteprednol 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis","volume":"24","author":"White","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2014.05.005_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02849993","article-title":"Comparison of tobramycin 0.3%\/dexamethasone 0.1% and tobramycin 0.3%\/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis","volume":"24","author":"Rhee","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib53","unstructured":"Zylet [package insert]. Tampa, FL: Bausch & Lomb Inc; 2013"},{"key":"10.1016\/j.jtos.2014.05.005_bib54","unstructured":"Tobradex [package insert]. Fort Worth, TX: Alcon Laboratories; 2009"},{"key":"10.1016\/j.jtos.2014.05.005_bib55","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1185\/03007990802231981","article-title":"Tolerability of loteprednol\/tobramycin versus dexamethasone\/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study","volume":"24","author":"Bartlett","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2014.05.005_bib56","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12325-012-0018-8","article-title":"Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis","volume":"29","author":"Belfort","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2014.05.005_bib57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A\u00a0controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib58","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1","volume":"24","author":"Stewart","year":"1998","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.jtos.2014.05.005_bib59","first-page":"177","article-title":"Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery","volume":"5","author":"Comstock","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","article-title":"Effects of loteprednol\/tobramycin versus dexamethasone\/tobramycin on intraocular pressure in healthy volunteers","volume":"27","author":"Holland","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1023\/A:1015849132396","article-title":"Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate","volume":"9","author":"Bodor","year":"1992","journal-title":"Pharm Res"},{"key":"10.1016\/j.jtos.2014.05.005_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X","article-title":"Soft drug design: general principles and recent applications","volume":"20","author":"Bodor","year":"2000","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jtos.2014.05.005_bib63","doi-asserted-by":"crossref","first-page":"789623","DOI":"10.1155\/2012\/789623","article-title":"Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate","volume":"2012","author":"Comstock","year":"2012","journal-title":"Int J Inflam"},{"key":"10.1016\/j.jtos.2014.05.005_bib64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/ICO.0b013e318207fc42","article-title":"Oral azithromycin for treatment of posterior blepharitis","volume":"30","author":"Igami","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","article-title":"The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction","volume":"19","author":"Yoo","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","article-title":"Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study","volume":"32","author":"Foulks","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2014.05.005_bib67","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","article-title":"Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction","volume":"154","author":"Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2014.05.005_bib68","unstructured":"Vargas JM, Aronowicz J, Shine WE, et\u00a0al. Short-term treatment of chronic blepharitis with oral minocycline [abstract]. Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA; May 4-8, 2003"},{"key":"10.1016\/j.jtos.2014.05.005_bib69","first-page":"57","article-title":"The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca","volume":"3","author":"Gumus","year":"2009","journal-title":"Clin Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012414001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012414001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T08:24:50Z","timestamp":1538382290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012414001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1542012414001268"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2014.05.005","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}